ArticleInternational journal of clinical oncology2024

First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.

Hiroki Ishihara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.